Dr. Daniel J. Drucker
MD, FRCPC, FRSC -- GLP-1 Discovery Pioneer
While experts do not endorse PeptidesInstitute.org, nor do we explicitly endorse any expert, the nature of regulation in this market has left people who are genuinely interested in the cutting edge of science to wade through a mix of opinions from experts of widely varying quality. It is our aim to provide you with sources who have done the research despite the legal challenges, for the betterment of humanity. Dr. Daniel J. Drucker is one of those people who has put their own name and reputation on the line in the pursuit of progress, and we cite them here respectfully. We ask you, the reader, to do your own research, drawing on the aggregate opinions of as many scientists, researchers, and experts as you can find. None of this is medical advice. Always consult a qualified healthcare provider before starting, stopping, or modifying any health protocol.
Why We Cite This Expert
Discoverer of the biological actions of GLP-1; the foundational scientific authority for the entire weight-loss peptide category. No serious discussion of semaglutide, tirzepatide, or retatrutide is complete without citing his mechanistic research.
Biography
Dr. Daniel J. Drucker is a University Professor of Medicine at the University of Toronto and a Senior Investigator at the Lunenfeld-Tanenbaum Research Institute at Sinai Health. He is recognized internationally as the discoverer of the biological actions of glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2), work that laid the foundation for the entire class of incretin-based therapies now used to treat type 2 diabetes and obesity.
His laboratory's research on GLP-1 biology provided the mechanistic basis for drugs such as semaglutide, tirzepatide, and retatrutide -- peptides that are reshaping how metabolic disease is understood and treated. Dr. Drucker has authored hundreds of peer-reviewed publications and is a Fellow of the Royal Society of Canada (FRSC) and the Royal College of Physicians of Canada (FRCPC).
Research Coverage
Peptides Covered by Drucker
Research areas this expert has written or spoken about.
Retatrutide
Triple Agonist Peptide for Weight Loss
Semaglutide
GLP-1 Peptide for Weight Loss
Tirzepatide
Dual Agonist Peptide for Weight Loss
Liraglutide
GLP-1 Receptor Agonist for Weight Loss
Cagrilintide
Long-Acting Amylin Analog for Weight Loss
Dulaglutide
Long-Acting GLP-1 Receptor Agonist for Weight Loss